Meeting
2014 Genitourinary Cancers Symposium
Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
Authors
Arun Azad
British Columbia Cancer Agency, Vancouver, BC, Canada
Arun Azad , Renee Lester , Daniel Yick Chin Heng , Bernhard J. Eigl , Kim N. Chi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 97)
DOI
10.1200/jco.2014.32.4_suppl.97
Abstract #
97
Poster Bd #
F14
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.
First Author: Syed A. Hussain
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2018 Genitourinary Cancers Symposium
Experience of a Brazilian oncological center using abiraterone acetate in metastatic castration-resistant prostate cancer patients.
First Author: Daniel D`Almeida Preto
Poster
2016 ASCO Annual Meeting
Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).
First Author: Johann S. De Bono